20.109(F11): MLD: Difference between revisions
No edit summary |
|||
| Line 9: | Line 9: | ||
* Curing a Heart Disease through the use of Fibrin scaffolds. | * Curing a Heart Disease through the use of Fibrin scaffolds. | ||
==Background Information== | ==Background Information== | ||
* http://www.springerlink.com/content/k028661713380485/fulltext.html | |||
"Fibrin is an attractive alternative biopolymer for cardiac tissue engineering because it can be easily formed into fibrillar networks, similar to type I collagen [54]. In addition, it has the potential to be autologous because it can be extracted from the patient’s blood, alleviating the risk of a foreign body reaction to the scaffold [55]. Due to its role in the body’s natural wound healing mechanism, fibrin gel is very bioactive, stimulating the cells entrapped in the gel to replace the initial scaffolding with their own extracellular matrix. This ultimately allows the construct to serve as a temporary scaffold [56], with the end stage graft being composed only of the patient’s own cells and the ECM that they create. In addition, fibrin has been FDA-approved as a surgical sealant and thus has a history of use in the clinical setting. Fibrin glue [20] and hydrogel scaffolds [37, 57, 58] have both been explored as possible cardiac grafts." | |||
==Research Problem and Goals== | ==Research Problem and Goals== | ||
==Project Details and Methods== | ==Project Details and Methods== | ||
==Predicted Outcomes== | ==Predicted Outcomes== | ||
==Necessary Resources== | ==Necessary Resources== | ||
Revision as of 19:05, 29 November 2011
WF Team Pink/Purple
- Michelle Fung
- Luis Juarez
- Dorma Flemister
Project Overview
- Fibrin and its uses as scaffold in tissue engineering and gene delivery.
- Curing a Heart Disease through the use of Fibrin scaffolds.
Background Information
"Fibrin is an attractive alternative biopolymer for cardiac tissue engineering because it can be easily formed into fibrillar networks, similar to type I collagen [54]. In addition, it has the potential to be autologous because it can be extracted from the patient’s blood, alleviating the risk of a foreign body reaction to the scaffold [55]. Due to its role in the body’s natural wound healing mechanism, fibrin gel is very bioactive, stimulating the cells entrapped in the gel to replace the initial scaffolding with their own extracellular matrix. This ultimately allows the construct to serve as a temporary scaffold [56], with the end stage graft being composed only of the patient’s own cells and the ECM that they create. In addition, fibrin has been FDA-approved as a surgical sealant and thus has a history of use in the clinical setting. Fibrin glue [20] and hydrogel scaffolds [37, 57, 58] have both been explored as possible cardiac grafts."
